StockDuty ← Dashboard Aug 17, 2026 03:16 PM ET
CatalystFDA/Bio

OCULAR GAINS ON EYEPOINT PHASE 3 WET AMD MISS - SEEKINGALPHA

Phase 3 wet AMD miss boosts Ocular’s competing therapy prospects.

What changed
Why it matters
Phase 3 wet AMD miss boosts Ocular’s competing therapy prospects.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →